Short Interest in Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Expands By 411.7%

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) was the target of a large growth in short interest in August. As of August 31st, there was short interest totaling 265,115 shares, a growth of 411.7% from the August 15th total of 51,809 shares. Based on an average daily volume of 1,250,016 shares, the days-to-cover ratio is currently 0.2 days. Approximately 6.3% of the shares of the company are sold short.

Insider Transactions at Bluejay Diagnostics

In other Bluejay Diagnostics news, major shareholder Financial Lp Hrt sold 34,938 shares of the business’s stock in a transaction dated Friday, July 10th. The shares were sold at an average price of $1.40, for a total value of $48,913.20. Following the completion of the sale, the insider owned 92,055 shares of the company’s stock, valued at $128,877. The trade was a 27.51% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 6.10% of the stock is owned by corporate insiders.

Institutional Trading of Bluejay Diagnostics

An institutional investor recently bought a new stake in Bluejay Diagnostics stock. Armistice Capital LLC bought a new position in Bluejay Diagnostics, Inc. (NASDAQ:BJDX) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 65,000 shares of the company’s stock, valued at approximately $43,000. Armistice Capital LLC owned approximately 9.15% of Bluejay Diagnostics as of its most recent SEC filing. 18.47% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages have recently commented on BJDX. Wall Street Zen raised shares of Bluejay Diagnostics from a “sell” rating to a “hold” rating in a report on Sunday, September 6th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Bluejay Diagnostics in a research report on Wednesday, June 24th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company has a consensus rating of “Sell”.

Bluejay Diagnostics Trading Down 7.8%

Bluejay Diagnostics stock traded down $0.08 during midday trading on Friday, reaching $0.93. The company’s stock had a trading volume of 95,945 shares, compared to its average volume of 2,574,783. The stock has a market cap of $4.16 million, a PE ratio of -0.13 and a beta of 0.91. Bluejay Diagnostics has a 52 week low of $0.82 and a 52 week high of $16.68. The business has a 50-day moving average price of $1.06 and a 200-day moving average price of $1.92.

Bluejay Diagnostics (NASDAQ:BJDX) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($1.12) earnings per share for the quarter, beating analysts’ consensus estimates of ($3,520.00) by $3,518.88.

Bluejay Diagnostics Company Profile

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.